Takeda Pharmaceutical Company Limited (TAK)

Business: Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide.

IPO Date: 27-Oct-2008

Pres, CEO & Representative Director: Mr. Christophe Weber

CFO & Representative Director: Mr. Constantine Saroukos

Listing: NYSE: TAK

Country: Japan

Headquarters: Tokyo,

Website: https://www.takeda.com

Market cap: $42,978.74 Mln

Revenue (TTM): JP¥3,569,006.00 Mln

Earnings (TTM): JP¥230,059.00 Mln

Cash: JP¥875,000.00 Mln

Total Debt: JP¥4,345,411.00 Mln

Insider's Holding: 0.01%

Liquidity: Low

52 Week range: $13.05 - 17.31

Shares outstanding: 3,105,400,064

10 Years Aggregate:

• CFO: JP¥4,435,536.00 Mln
• EBITDA: JP¥4,947,477.00 Mln
• Net Profit: JP¥1,233,550.00 Mln